Given results of the ELEVATE-RR study, would you consider use of acalabrutinib in all patients with previously treated CLL, or restrict it to certain patient populations?

Efficacy and safety are both important for evaluating new therapies. The ELEVATE-RR study demonstrated equivalent efficacy with a hazard ratio of 1.0 which indicates response duration was identical. Notably, several indications of safety were better which then would tilt the benefit to using an alte...

I am using acalabrutinib for all patients including in the frontline setting. The data with ELEVATE-RR clearly shows better safety profile with acalabrutinib versus ibrutinib. There is no reason to believe that the safety profile will be different in the frontline setting.

Therefore, in my practice,...

All patients who have not had a prior covalent BTK inhibitor, or who had one but came off for an adverse event without disease progression, would be candidates for acalabrutinib.